Proactive Investors USA & Canada

Afinitor Study Meets Primary Endpoint
Drug Discovery & Development
A Phase 3 study of Novartis' Afinitor (everolimus) tabletsin patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, ...
Novartis drug Afinitor® effective in patients with non-cancerous kidney ...Reuters (press release)
Novartis' Afinitor Study Show Positive Results In Kidney TumorsRTT News

all 22 news articles »